研究等業績 - その他 - 南條　博

病理診断試料の薄切における切削力および薄切片厚さの検討

佐藤 寛恭, 北村 峻祐, 中川 佑貴, 南條 博, 赤上 陽一, 中村 竜太, 久住 孝幸, 吉野 雅彦

精密工学会学術講演会講演論文集 ( 公益社団法人 精密工学会 )  2022S ( 0 ) 503 - 504   2022年03月

<p>癌などの病理診断のために患部組織をパラフィンに包埋し、厚さ数μmの切片に薄切し顕微鏡観察用プレパラートを作製する必要がある。本研究ではその薄切片品質を向上し安定化させことを目的としている。本報では種々の生物試料包埋パラフィンブロックを試料とし、薄切の切削力および薄切片厚さを実験的に測定した結果、および力学的モデルに基づき切削力および薄切片厚さに影響を及ぼす因子に関する検討について報告する。</p>

DOI CiNii Research

Intraoperative rapid immunohistochemistry with noncontact antibody mixing for undiagnosed pulmonary tumors

Imai K.

Cancer Science ( Cancer Science )  114 ( 2 ) 702 - 711   2022年

DOI

Collision of Epstein–Barr virus-positive and -negative gastric cancer, diagnosed by molecular analysis: a case report

Miyabe K.

BMC Gastroenterology ( BMC Gastroenterology )  21 ( 1 )   2021年12月

DOI

Disorganization of intercalated discs in dilated cardiomyopathy

Ito Y.

Scientific Reports ( Scientific Reports )  11 ( 1 )   2021年12月

DOI

Altering phosphoinositides in high-fat diet-associated prostate tumor xenograft growth

Huang M.

MedComm ( MedComm )  2 ( 4 ) 756 - 764   2021年12月

DOI

病理診断のための薄切片厚さの高精度化法の検討

北村 峻祐, 丸山 祐, 中西 将也, 中川 佑貴, 南條 博, 赤上 陽一, 中村 竜太, 久住 孝幸, 吉野 雅彦

精密工学会学術講演会講演論文集 ( 公益社団法人 精密工学会 )  2021A ( 0 ) 283 - 284   2021年09月

<p>癌などの病理診断のために、パラフィンに包埋した患部組織を厚さ数μmの切片に薄切し、組織の顕微鏡観察用プレパラートを作製する必要がある。プレパラートの薄切片厚さが顕微鏡の観察画像に影響するため、正確な厚さの薄切片を作製することが診断効率、診断精度向上のために重要である。そこで本研究では、薄切の力学的機構を明らかにし、薄切片厚さの高精度化法を検討する。</p>

DOI CiNii Research

Macrophage inhibitory cytokine-1 induced by a high-fat diet promotes prostate cancer progression by stimulating tumor-promoting cytokine production from tumor stromal cells

Huang M.

Cancer Communications ( Cancer Communications )  41 ( 5 ) 389 - 403   2021年05月

DOI

Detection of MED12 mutations in mesenchymal components of uterine adenomyomas

Kito M.

Human Pathology ( Human Pathology )  109   31 - 36   2021年03月

DOI

Outcomes of definitive chemoradiotherapy for stage iva (T4b vs. n4) esophageal squamous cell carcinoma based on the japanese classification system: A retrospective single-center study

Wada Y.

Cancers ( Cancers )  13 ( 1 ) 1 - 12   2021年01月

DOI

CD147 promotes invasion and MMP-9 expression through MEK signaling and predicts poor prognosis in hypopharyngeal squamous cell carcinoma

Suzuki S.

Advances in Clinical and Experimental Medicine ( Advances in Clinical and Experimental Medicine )  30 ( 1 ) 41 - 48   2021年

DOI

Harmonization across programmed death ligand 1 (PD-L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing

Matsuo T.

Thoracic Cancer ( Thoracic Cancer )  12 ( 8 ) 1187 - 1194   2021年

DOI

Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease

Kaga H.

International Journal of Hematology ( International Journal of Hematology )  115 ( 1 ) 129 - 134   2021年

DOI

Deep Angiomyxoma of the Thigh That Is Difficult to Diagnose: A Case Report and Literature Review

Tsuchie H.

Acta Medica Okayama ( Acta Medica Okayama )  75 ( 5 ) 653 - 657   2021年

Stapler-lavage cytology using a new rapid immunocytochemistry for evaluating surgical margin status after pulmonary sublobar resection

Kurihara N.

General Thoracic and Cardiovascular Surgery ( General Thoracic and Cardiovascular Surgery )  70 ( 4 ) 359 - 365   2021年

DOI

Successful salvage therapy of D-PACE combined with pomalidomide in a patient with triple-class refractory secondary plasma cell leukemia

KOBAYASHI Takahiro, KUROKI Jun, KOBAYASHI Isuzu, SAITO Masaya, FUJISHIMA Masumi, UBUKAWA Kumi, FUJISHIMA Naohito, KAMEOKA Yoshihiro, NANJO Hiroshi, TAKAHASHI Naoto

International Journal of Myeloma ( 一般社団法人 日本骨髄腫学会 )  11 ( 4 ) 27 - 31   2021年

<p>Novel agents have dramatically improved the prognosis of multiple myeloma (MM). However, the prognosis of MM resistant to several classes of novel agents and secondary plasma cell leukemia (sPCL) is poor. In such cases, cisplatin, doxorubicin, cyclophosphamide, and etoposide (PACE)-based regimens are considered in combination with dexamethasone, thalidomide, and bortezomib. Herein, we report the case of a 47-year-old patient with Bence Jones Protein (BJP)-λ-type MM, primary refractory to bortezomib, lenalidomide, and dexamethasone (VRd) therapy, which subsequently progressed to sPCL accompanied with the acquired 17p deletion. Although the patient was also refractory to daratumumab-based therapy (triple-class refractory MM), he was successfully treated with dexamethasone and pomalidomide with PACE (DP-PACE) therapy, and after three cycles, he achieved complete remission (CR) and bridged to allogeneic stem cell transplantation (SCT). To the best of our knowledge, this is the first report of DP-PACE regimen, which may be considered for patients with relapsed refractory MM as a bridge to SCT.</p>

DOI CiNii Research

Clinicopathological and molecular analyses of linearly expanded epithelial cells with β-catenin alterations, “β-catenin signature”, in the normal fallopian tube

Koyama K.

Histopathology ( Histopathology )  77 ( 6 ) 880 - 889   2020年12月

DOI

Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas

Furuya M.

Journal of Clinical Pathology ( Journal of Clinical Pathology )  73 ( 12 ) 819 - 825   2020年12月

DOI

Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report

Ono T.

Acta Neurochirurgica ( Acta Neurochirurgica )  162 ( 12 ) 3019 - 3024   2020年12月

DOI

Intraoperative diagnosis of lymph node metastasis during segmentectomy for non-small cell lung cancer by rapid immunohistochemistry using noncontact alternating current electric field mixing

Imai K.

Thoracic Cancer ( Thoracic Cancer )  11 ( 12 ) 3547 - 3554   2020年12月

DOI

High TLR4 expression predicts a poor prognosis after esophagectomy for advanced thoracic esophageal squamous cell carcinoma

Sato Y.

Esophagus ( Esophagus )  17 ( 4 ) 408 - 416   2020年10月

DOI